Gene · 116085
Papers1,555
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 1,555
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Gout therapy updated. | Ther Adv Musculoskelet Dis | 2025 | 41146690 | PubTator, text mining | PubMed |
| Association of single-nucleotide polymorphisms in SLC2A9, SLC22A12 and SLC22A11 genes with hyperuricemia in the Chinese Tibetan population. | Medicine (Baltimore) | 2025 | 41137353 | PubTator, text mining | PubMed |
Switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, may substantially reduce serum urate levels, through URAT1 inhibition, potentially without adversely affecting ABCG2 function: findings from the SWITCH SURI study. | Front Endocrinol (Lausanne) | 2025 | 41113711 | PubTator, text mining | PubMed |
| Crystal clear - Part II: the role of uric acid in cardiorenal disease. | Eur J Intern Med | 2025 | 41111035 | PubTator, text mining | PubMed |
| Modulation of NLRP3 inflammasome and uric acid metabolism by small molecule pectin from Premna ligustroides Hemsl leaves: Implications for hyperuricemia management. | Int J Biol Macromol | 2025 | 41075904 | PubTator, text mining | PubMed |
| Molecular interplay between TXNIP and GLUT9 underlies uric acid transport dysregulation in vitro under hyperuricemic stress. | Eur J Med Res | 2025 | 41068947 | PubTator, text mining | PubMed |
| URAT1 and GLUT9 as drug targets in gout: progress in transporter-directed therapies and delivery technologies. | Inflammopharmacology | 2025 | 41065961 | PubTator, text mining | PubMed |
| Potential Transmembrane Proteins-transporters of Chelidonic Acid for its Intracellular Uptake: In Silico Simulation. | Pharm Res | 2025 | 41062799 | PubTator, text mining | PubMed |
| Hyperuricemia in Chronic Kidney Disease: Emerging Pathophysiology and a Novel Therapeutic Strategy. | Int J Mol Sci | 2025 | 41009566 | PubTator, text mining | PubMed |
| Anti-hyperuricemic triterpene saponins from the roots of Achyranthes bidentata. | Nat Prod Res | 2025 | 40990100 | PubTator, text mining | PubMed |
| Investigation of the Inhibitory Effects of Fatty Acid Derivatives on URAT1 Function, a Renal Urate Re-Absorber. | J Nutr Sci Vitaminol (Tokyo) | 2025 | 40887282 | PubTator, text mining | PubMed |
| Choline transporter-like protein 1 in tongue squamous cell carcinoma: implications for cell proliferation and differentiation. | Sci Rep | 2025 | 40883446 | PubTator, text mining | PubMed |
| Next-generation RNA sequencing of spatially mapped material from human body donors for testing the impact of fetal environments on the liver transcriptome. | Sci Rep | 2025 | 40858696 | PubTator, text mining | PubMed |
| Advances in Xanthine Oxidase Inhibition: A Review of Potential Bioactive Synthetic Compounds. | Arch Pharm (Weinheim) | 2025 | 40838763 | PubTator, text mining | PubMed |
| Tophaceous gout in the lumbar spinal canal mimicking epidural spinal tumor in a male adolescent: A case report. | Medicine (Baltimore) | 2025 | 40826728 | PubTator, text mining | PubMed |
| Serum uric acid, renal status, cardiovascular-kidney-metabolic syndrome and drug therapy, a wide-angled Mendelian randomization analysis. | Am Heart J Plus | 2025 | 40809993 | PubTator, text mining | PubMed |
| Gout management: Patent analytics and computational drug design explores URAT1 inhibitors landscape. | PLoS One | 2025 | 40802708 | PubTator, text mining | PubMed |
| Quantitative evaluation of clinical efficacy and safety of uric acid-lowering drugs: A modeling analysis of literature aggregate data. | Semin Arthritis Rheum | 2025 | 40780110 | PubTator, text mining | PubMed |
| 17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway. | Drug Des Devel Ther | 2025 | 40756265 | PubTator, text mining | PubMed |
| Gut microbiome remodeling in chronic kidney disease: implications of kidney replacement therapies and therapeutic interventions. | Front Med (Lausanne) | 2025 | 40735439 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/116085/papers?page=4